Catechols in post-mortem brain of patients with Parkinson disease.
about
Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson diseaseChanges in Rat 50-kHz Ultrasonic Vocalizations During Dopamine Denervation and Aging: Relevance to NeurodegenerationCatecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disordersVesicular integrity in Parkinson's diseaseCellular localization of dieldrin and structure-activity relationship of dieldrin analogues in dopaminergic cellsReduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivoBenomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease.Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease.Molecular and biochemical characterization of Mottled-dappled, an embryonic lethal Menkes disease mouse modelLinking neuroscience with modern concepts of impulse control disorders in Parkinson's disease.Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases.Improving response inhibition in Parkinson's disease with atomoxetine.Aberrant functional connectivity within the basal ganglia of patients with Parkinson's diseaseCerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies.Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease.Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.Resting state functional connectivity of the striatum in Parkinson's disease.Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures.Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease.Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseases.Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRIConcepts of scientific integrative medicine applied to the physiology and pathophysiology of catecholamine systems.Multiple modes of impulsivity in Parkinson's disease.DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function.Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseasesSympathetic neuroimaging.Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease.Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis.New tricks for old dogmas: optogenetic and designer receptor insights for Parkinson's diseaseThe vesicular monoamine transporter 2: an underexplored pharmacological target.Atomoxetine restores the response inhibition network in Parkinson's disease.Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.Linking Stress, Catecholamine Autotoxicity, and Allostatic Load with Neurodegenerative Diseases: A Focused Review in Memory of Richard Kvetnansky.Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson's disease.Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.Antioxidant-Mediated Modulation of Protein Reactivity for 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopamine Metabolite.
P2860
Q24632904-092F5773-5826-4DDC-BB1D-49102784F033Q26786494-5013E48C-4ED6-465E-9C56-BA6105BBC21FQ26826093-9497C63B-F01A-4126-85B3-68E5CD1F5BF0Q28385737-E9BF76B5-2253-42AA-8E5B-299EC66D0B5BQ28387863-D6F4A211-4D37-4E02-A070-299EE0A27A67Q33724885-4233D9C2-718C-4711-9463-7CFDB5823C72Q33896138-6103B7D1-CBFB-4F22-A078-0138C38B5B0AQ33919548-B2D71FB9-08DD-403D-AB18-E8501E2E0767Q34065897-B6E4839D-8E72-4C86-BF47-6DB5F32B13D8Q34181738-AC5C2A86-57FB-46E8-919D-D05AC17A35BEQ34657353-3CAD25BF-7EE0-4354-A4B5-341625F4E8FAQ35054558-10F4B6D9-9705-4E1A-9979-D0D93F8C76FCQ35142854-B28F3937-D784-4653-9B6F-3574BC6383C8Q35264006-B2153EEC-1422-46C2-A1D7-82E29B7E0E7BQ35759065-413082D7-326C-480C-AB4B-0DD9E2F4CAACQ35986671-1548FDD2-6898-4FCC-B4E2-D40D636465A8Q36011221-29AD96AB-9134-4E86-A8D3-308ED0F1276AQ36154790-995AB7C9-9923-450F-82AE-AE8B23FEF5A9Q36282886-A966FEAE-BB66-41F3-86FD-D88711350BEAQ36445937-B8AD1662-780E-4EC3-892A-F344E98D16ABQ36474693-2F6D3158-411E-4DA8-9AB9-DF46EEB3B3CCQ36762203-4EA5E73C-AFD5-419C-A30A-9D6808DB137CQ36870256-6A140143-DAE6-48C4-A129-E43F1347C294Q36987273-EB31FA07-ACC6-44D2-91C2-D8C4542A93D9Q36990782-F8692A0C-EE46-4DFE-9B40-EBAF1288A80EQ36992085-EEB70DBD-040D-42BB-AF6E-DDD90107C6DAQ37499687-38A5B8EB-B6AC-4617-93E5-FEB11DBC8C92Q37584540-36956218-FC2C-431B-82CA-2621BCC4354CQ37590347-294A8F76-7A9A-4E3E-BF3E-F41B9A484F49Q37614069-F981BCCD-2D23-4742-A4C8-E475C5683AEDQ37647815-9E96EE42-FB5B-4144-870F-6CC97133058CQ37957562-F1DB64D1-242F-4E24-B84E-B7F40F04D6D2Q38075712-B412D41C-8B4D-4A5F-81B3-ECECF3D717ACQ38176494-2534CAD0-D86A-4EEE-B415-775538D4AE8BQ38848619-8B870A55-9531-4B8D-B7A8-343293687AB0Q38926644-6FCEB00B-43F0-47A4-9FEE-66235714A5BEQ39294770-95191CDC-D68C-4CB7-BA80-A1355308A6EAQ39607510-35A62DFC-D51D-4243-82BC-224B89EFB062Q41655727-943D741C-3992-4AA1-B0B8-6BBB9FA4C693Q42196555-5AD10F88-0A50-4D68-B02F-7E5D1330FD8A
P2860
Catechols in post-mortem brain of patients with Parkinson disease.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Catechols in post-mortem brain of patients with Parkinson disease.
@ast
Catechols in post-mortem brain of patients with Parkinson disease.
@en
type
label
Catechols in post-mortem brain of patients with Parkinson disease.
@ast
Catechols in post-mortem brain of patients with Parkinson disease.
@en
prefLabel
Catechols in post-mortem brain of patients with Parkinson disease.
@ast
Catechols in post-mortem brain of patients with Parkinson disease.
@en
P2093
P2860
P1476
Catechols in post-mortem brain of patients with Parkinson disease.
@en
P2093
P2860
P304
P356
10.1111/J.1468-1331.2010.03246.X
P577
2010-11-12T00:00:00Z